David A. Siegel Avidity Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 16,400 shares of RNA stock, worth $546,120. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,400
Previous 81,900
79.98%
Holding current value
$546,120
Previous $3.76 Million
87.34%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding RNA
# of Institutions
257Shares Held
100MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11MShares$368 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$314 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$287 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$264 Million3.76% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.5MShares$250 Million3.18% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.74B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...